Figure 2: Overall survival (A) and disease-free survival (B) curves for two groups defined by low and high expression of XB130 in patients with osteosarcoma. The patients with high XB130 expression had a significantly worse 5-year overall and disease-free survival rate than those with low XB130 staining (both P< 0.001)